| Předmět: |
|
| Zdroj: |
Vaccine Weekly; 12/8/2023, p8221-8221, 1p |
| Abstrakt: |
A patent application has been filed for the use of engineered adeno-associated virus (AAV) vectors as a delivery system for genes in humans. AAVs are non-pathogenic viruses that have been extensively tested for safety and long-term expression of transgenes. The invention aims to insert large immunogenic proteins into the AAV capsid to create a carrier for subunit vaccines. This technology could be used to develop effective therapeutic and prophylactic vaccines for infectious diseases such as COVID-19 or other emerging coronaviruses. The invention has potential applications in gene therapy, vaccine development, and the treatment or prevention of various diseases. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
